Veridix AI, a leading AI-powered CRO, has unveiled its new protocol digitization capabilities to revolutionize the clinical trial creation process. By leveraging natural language processing and AI technologies, this innovative approach automates the extraction of structured data elements from unstructured text, reducing creation time by up to 30%. This cutting-edge solution is integrated into Veridix AI’s Advantage eClinical Cloud platform, paving the way for faster and more efficient clinical trial workflows.
The protocol digitization technology not only streamlines the creation of database studies but also enhances data quality through automated visit schedules and eCRF predictions with over 82% accuracy. By harnessing the power of AI, Veridix AI is transforming traditional manual processes into automated, error-free workflows. This advancement positions the company at the forefront of innovation in the clinical research industry.
Rama Kondru, Chief Executive Officer of Veridix AI, believes that the digitization of protocols has the potential to revolutionize the clinical research process, paving the way for greater efficiency and accuracy. This new technology allows data managers to focus on value-added tasks while automating tedious processes, leading to enhanced productivity and improved outcomes for clinical trials.
Sastry Chilukuri, Chief Executive Officer of Emmes Group, highlights the impact of this unique capability on study creation processes across their entire project portfolio. With over 40 study buildings already benefiting from this technology, Emmes Group is committed to harnessing next-generation technologies and AI capabilities to enhance clinical trials and deliver programs faster and more efficiently.
The Emmes Group, a leading CRO dedicated to advancing public health and biopharmaceutical innovation, is at the forefront of transforming the future of clinical research. With a focus on technology and AI-driven solutions, the company is committed to accelerating the pace of clinical trials and bringing new treatments to patients faster. Through a combination of operational excellence and scientific expertise, Emmes Group is shaping the future of clinical research.
Veridix AI’s protocol digitization capabilities represent a significant step forward in modernizing clinical research and enhancing the efficiency of clinical trial workflows. By automating the creation of structured data elements and eCRFs, this innovative solution is poised to revolutionize the industry and usher in a new era of AI-powered clinical research. For more information, visit http://www.veridixai.com.
